SAN DIEGO--(BUSINESS WIRE)--Today, DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announced the expansion of its U.S. Sales Team, with the addition of two Regional Sales Managers. The expanded sales team will focus its efforts on the commercial launch of DermTech’s Pigmented Lesion Assay (for Melanoma Associated Gene Expression) and non-invasive Skin Biopsy Kit to dermatologist and other physician offices across the US. The Pigmented Lesion Assay helps clinicians non-invasively assess atypical pigmented lesions (often referred to as moles) for the presence or absence of gene signatures consistent with melanoma, the most deadly form of skin cancer.
“We could not be happier with this carefully selected team of talented professionals to expand our physician office sales presence. Each of them possesses an entrepreneurial spirit, a commitment to excellence, and a belief in the benefits of our technology to both patient care and patient outcomes”
“We could not be happier with this carefully selected team of talented professionals to expand our physician office sales presence. Each of them possesses an entrepreneurial spirit, a commitment to excellence, and a belief in the benefits of our technology to both patient care and patient outcomes,” said Steve Kemper, CPA, MBA, MS and DermTech’s Chief Financial Officer.
ABOUT DermTech
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.
Contacts
DermTech, Inc.
Sarah Dennison, MBA
VP of Marketing
(858) 450-4222
sdennison@dermtech.com
Help employers find you! Check out all the jobs and post your resume.
